When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?
J Clin Oncol
.
2014 Dec 20;32(36):4173-4.
doi: 10.1200/JCO.2014.58.1678.
Epub 2014 Nov 17.
Authors
Nai-Kong V Cheung
1
,
Shakeel Modak
1
,
Irina Ostrovnaya
1
,
Stephen S Roberts
1
,
Ellen M Basu
1
,
Kim Kramer
1
,
Brian H Kushner
2
Affiliations
1
Memorial Sloan-Kettering Cancer Center, New York, NY.
2
Memorial Sloan-Kettering Cancer Center, New York, NY
[email protected]
.
PMID:
25403224
DOI:
10.1200/JCO.2014.58.1678
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Marrow Transplantation*
Humans
Isotretinoin / therapeutic use*
Neuroblastoma / therapy*
Substances
Isotretinoin